A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma

Cancer Immunology, Immunotherapy

Volumn 64, Issue 10, 2015, Pages 1251-1260

  Krishnadas, Deepa K ^a   Shusterman, Suzanne ^b   Bai, Fanqi ^a   Diller, Lisa ^b   Sullivan, Janice E ^a   Cheerva, Alexandra C ^a   George, Rani E ^b   Lucas, Kenneth G ^a  

^a University of Louisville School of Medicine   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Cancer germline genes; Decitabine; Dendritic cell vaccine; Immunotherapy; Neuroblastoma; Sarcoma

Indexed keywords

ALANINE AMINOTRANSFERASE; DECITABINE; DENDRITIC CELL VACCINE; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 3; NY ESO 1 ANTIGEN; AZACITIDINE; CANCER VACCINE; CTAG1B PROTEIN, HUMAN; MAGEA1 PROTEIN, HUMAN; MAGEA3 PROTEIN, HUMAN; MELANOMA ANTIGEN; MEMBRANE PROTEIN; PEPTIDE FRAGMENT; TUMOR ANTIGEN; TUMOR PROTEIN;

ADOLESCENT; ADULT; ARTICLE; BONE MARROW SUPPRESSION; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CELLULAR IMMUNITY; CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG FEVER; DRUG TARGETING; DRUG TOLERABILITY; EWING SARCOMA; FEASIBILITY STUDY; HUMAN; IMMUNE RESPONSE; NEUROBLASTOMA; OSTEOSARCOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RHABDOMYOSARCOMA; T LYMPHOCYTE; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; CELL CULTURE; CELL PROLIFERATION; CLINICAL TRIAL; DENDRITIC CELL; DRUG EFFECTS; FEMALE; IMMUNOLOGY; MALE; MULTIMODALITY CANCER THERAPY; PRESCHOOL CHILD; RECURRENT DISEASE; SARCOMA; TRANSPLANTATION;

ADOLESCENT; ANTIGENS, NEOPLASM; AZACITIDINE; CANCER VACCINES; CELL PROLIFERATION; CELLS, CULTURED; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DENDRITIC CELLS; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MELANOMA-SPECIFIC ANTIGENS; MEMBRANE PROTEINS; NEOPLASM PROTEINS; NEUROBLASTOMA; PEPTIDE FRAGMENTS; RECURRENCE; SARCOMA; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 84940724549     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-015-1731-3     Document Type: Article

References (34)

1. Igne FH, Krammer PH (2002) Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leukoc Biol 71(6):907–920
2. Scanlan MJ, Simpson AJ, Old LJ (2004) The cancer/testis genes: review, standardization, and commentary. Cancer Immun 4:1
3. Pollack SM, Loggers ET, Rodler ET, Yee C, Jones RL (2011) Immune-based therapies for sarcoma. Sarcoma 2011:438940
4. Lee SY, Obata Y, Yoshida M, Stockert E, Williamson B, Jungbluth AA et al (2003) Immunomic analysis of human sarcoma. Proc Natl Acad Sci USA 100(5):2651–2656
5. Nicholaou T, Ebert L, Davis ID, Robson N, Klein O, Maraskovsky E et al (2006) Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1. Immunol Cell Biol 84(3):303–317
6. Wolfl M, Jungbluth AA, Garrido F, Cabrera T, Meyen-Southard S, Spitz R et al (2005) Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastoma. Cancer Immunol Immunother 54(4):400–406
7. Jacobs JF, Brasseur F, Hulsbergen-van de Kaa CA, van de Rakt MW, Figdor CG, Adema GJ et al (2007) Cancer-germline gene expression in pediatric solid tumors using quantitative real-time PCR. Int J Cancer 120(1):67–74
8. Liu XF, Helman LJ, Yeung C, Bera TK, Lee B, Pastan I (2000) XAGE-1, a new gene that is frequently expressed in Ewing’s sarcoma. Cancer Res 60(17):4752–4755
9. Foell JL, Hesse M, Volkmer I, Schmiedel BJ, Neumann I, Staege MS (2008) Membrane-associated phospholipase A1 beta (LIPI) Is an Ewing tumour-associated cancer/testis antigen. Pediatr Blood Cancer 51(2):228–234
10. Weber J, Salgaller M, Samid D, Johnson B, Herlyn M, Lassam N et al (1994) Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2′-deoxycytidine. Cancer Res 54(7):1766–1771
11. Adair SJ, Hogan KT (2009) Treatment of ovarian cancer cell lines with 5-aza-2′-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules. Cancer Immunol Immunother 58(4):589–601
12. George RE, Lahti JM, Adamson PC, Zhu K, Finkelstein D, Ingle AM et al (2010) Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: a Children’s Oncology Group study. Pediatr Blood Cancer 55(4):629–638
13. Yang H, Hoshino K, Sanchez-Gonzalez B, Kantarjian H, Garcia-Manero G (2005) Antileukemia activity of the combination of 5-aza-2′-deoxycytidine with valproic acid. Leuk Res 29(7):739–748
14. Issa JP, Gharibyan V, Cortes J, Jelinek J, Morris G, Verstovsek S et al (2005) Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol 23(17):3948–3956
15. Bao L, Dunham K, Lucas K (2011) MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing. Cancer Immunol Immunother 60(9):1299–1307
16. Krishnadas DK, Bao L, Bai F, Chencheri SC, Lucas K (2014) Decitabine facilitates immune recognition of sarcoma cells by upregulating CT antigens, MHC molecules, and ICAM-1. Tumour Biol 35(6):5753–5762
17. Chianese-Bullock KA, Pressley J, Garbee C, Hibbitts S, Murphy C, Yamshchikov G et al (2005) MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma. J Immunol 174(5):3080–3086
18. Davis ID, Chen W, Jackson H, Parente P, Shackleton M, Hopkins W, Chen Q et al (2004) Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci USA 101(29):10697–10702
19. Odunsi K, Matsuzaki J, James SR, Mhawech-Fauceglia P, Tsuji T, Miller A et al (2014) Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer. Cancer Immunol Res 2(1):37–49
20. Schwartz GJ, Gauthier B (1985) A simple estimate of glomerular filtration rate in adolescent boys. J Pediatr 106(3):522–526
21. Krishnadas DK, Shapiro T, Lucas K (2013) Complete remission following decitabine/dendritic cell vaccine for relapsed neuroblastoma. Pediatrics 131(1):e336–e341
22. Arpinati M, Green CL, Heimfeld S, Heuser JE, Anasetti C (2000) Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood 95(8):2484–2490
23. Goodyear O, Agathanggelou A, Novitzky-Basso I, Siddique S, McSkeane T, Ryan G et al (2010) Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood 116(11):1908–1918
24. Wolfl M, Kuball J, Ho WY, Nguyen H, Manley TJ, Bleakley M et al (2007) Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities. Blood 110(1):201–210
25. Zhu Y, Chen L (2014) CD137 as a biomarker for tumor-reactive T cells: finding gold in the desert. Clin Cancer Res 20(1):3–5
26. Akers SN, Odunsi K, Karpf AR (2010) Regulation of cancer germline antigen gene expression: implications for cancer immunotherapy. Future Oncol 6(5):717–732
27. Mackensen A, Herbst B, Chen JL, Köhler G, Noppen C, Herr W, Spagnoli GC et al (2000) Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. Int J Cancer 86(3):385–392
28. Bender A, Karbach J, Neumann A, Jäger D, Al-Batran SE, Atmaca A, Weidmann E et al (2007) LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer. Cancer Immun 7:16
29. Emens LA, Asquith JM, Leatherman JM, Kobrin BJ, Petrik S, Laiko M, Levi J et al (2009) Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor–secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. J Clin Oncol 27(35):5911–5918
30. King IL, Kroenke MA, Segal BM (2010) GM-CSF-dependent, CD103+ dermal dendritic cells play a critical role in Th effector cell differentiation after subcutaneous immunization. J Exp Med 207(5):953–961
31. Vadhan-Raj S, Broxmeyer HE, Hittelman WN, Papadopoulos NE, Chawla SP, Fenoglio C et al (1992) Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: protection at the progenitor cell level. J Clin Oncol 10(8):1266–1277
32. Rapoport AP, Aqui NA, Stadtmauer EA, Vogl DT, Fang HB, Cai L et al (2011) Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. Blood 117(3):788–797
33. Rapoport AP, Stadtmauer EA, Aqui N, Vogl D, Chew A, Fang HB et al (2009) Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of costimulated autologous T cells. Clin Cancer Res 15(13):4499–4507
34. Sabbatini P, Tsuji T, Ferran L, Ritter E, Sedrak C, Tuballes K et al (2012) Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clin Cancer Res 18(23):6497–6508